NCT01583816View on ClinicalTrials.gov

Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions

PHASE2CompletedINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

June 30, 2014

Conditions
Actinic Keratosis
Interventions
DRUG

Resiquimod 0.03%

topical application

DRUG

Resiquimod 0.01%

topical application

DRUG

placebo

topical application

Trial Locations (10)

Unknown

Hauttumorcentrum Charité (HTCC), Berlin

Medizinisches Zentrum Bonn - Friedensplatz, Bonn

Hautzentrum, Düsseldorf

Johannes Wesling Klinikum Minden, Minden

KLINIKUM VEST GmbH Knappschaftskrankenhaus, Recklinghausen

Kantonsspital Aarau, Aarau

Universitätsspital Basel, Basel

Inselspital, Bern

Kantonsspital St.Gallen, Sankt Gallen

Universitaetsspital Zurich, Zurich

All Listed Sponsors
lead

Spirig Pharma Ltd.

INDUSTRY

NCT01583816 - Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions | Biotech Hunter | Biotech Hunter